

Jipan Xie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/448454/publications.pdf>

Version: 2024-02-01

78
papers

935
citations

623188

14
h-index

525886

27
g-index

81
all docs

81
docs citations

81
times ranked

1241
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Data for Healthcare Research in China: Call for Actions. <i>Value in Health Regional Issues</i> , 2022, 27, 72-81.	0.5	8
2	Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models. <i>Pharmacoeconomics</i> , 2022, 40, 257-268.	1.7	1
3	Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit. <i>Clinical Therapeutics</i> , 2022, 44, 52-66.e2.	1.1	6
4	Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study. <i>Cardiology and Therapy</i> , 2022, 11, 249-267.	1.1	5
5	Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World Settings. <i>Rheumatology and Therapy</i> , 2022, 9, 265-283.	1.1	1
6	Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial. <i>Journal of Medical Economics</i> , 2022, 25, 51-58.	1.0	9
7	An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies. <i>Haemophilia</i> , 2021, 27, e51-e59.	1.0	15
8	HSR21-063: Treatment Patterns Among Patients With EGFR Mutated Metastatic NSCLC Who Have Discontinued EGFR-TKI and Platinum-Based Chemotherapy Regimens. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, HSR21-063.	2.3	0
9	Treatment patterns following first-line pertuzumab + trastuzumab in patients with HER2+ metastatic breast cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18746-e18746.	0.8	1
10	Resource use and costs in patients with relapsed/refractory diffuse large C-cell lymphoma who initiated a third-line therapy in the post CAR-T era: A longitudinal outlook.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19560-e19560.	0.8	0
11	Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support. <i>Clinical Nutrition ESPEN</i> , 2021, 43, 420-427.	0.5	11
12	Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving 3 therapy lines in post-CAR-T era. <i>Current Medical Research and Opinion</i> , 2021, 37, 1789-1798.	0.9	3
13	Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States. <i>Pediatric Rheumatology</i> , 2021, 19, 143.	0.9	1
14	Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 1115-1123.	1.0	11
15	Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective. <i>Blood</i> , 2021, 138, 112-112.	0.6	3
16	Abstract 10969: Estimated Number Needed to Treat with Mavacamten vs Placebo to Improve Functional Capacity and Left Ventricular Outflow Tract Obstruction in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2021, 144, .	1.6	4
17	Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 44, 119-128.	1.3	38
18	The Development of Health Technology Assessment in Asia: Current Status and Future Trends. <i>Value in Health Regional Issues</i> , 2020, 21, 39-44.	0.5	31

#	ARTICLE	IF	CITATIONS
19	Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. <i>Adv Ther</i> (2019);36(8):2147-2160. doi:10.1007/s12325-019-00991-w. <i>Advances in Therapy</i> , 2020, 37, 955-957.	1.3	0
20	Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China. <i>Journal of Medical Economics</i> , 2020, 23, 1630-1639.	1.0	3
21	Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era. <i>Kidney Medicine</i> , 2020, 2, 589-599.e1.	1.0	16
22	Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 50.	0.6	7
23	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. <i>Cancer Research</i> , 2020, 80, 5427-5434.	0.4	77
24	Real-world analysis of haemophilia patients in China: A single centre's experience. <i>Haemophilia</i> , 2020, 26, 584-590.	1.0	10
25	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1096-1104.	2.3	33
26	The cost-effectiveness of low-dose budesonide as a Step 2 treatment for pediatric asthma in China. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1141-1151.	0.6	0
27	Utilization of anti-HER2 regimens among HER2-positive metastatic breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 282-282.	0.8	0
28	Characteristics and Treatment Patterns of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies. <i>Blood</i> , 2020, 136, 4-5.	0.6	1
29	Transparency in Health Economic Modeling: Options, Issues and Potential Solutions. <i>Pharmacoeconomics</i> , 2019, 37, 1349-1354.	1.7	8
30	Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review. <i>Journal of Medical Economics</i> , 2019, 22, 1141-1152.	1.0	19
31	Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Advances in Therapy</i> , 2019, 36, 950-961.	1.3	19
32	Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. <i>Blood Advances</i> , 2019, 3, 2986-2994.	2.5	70
33	Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States. <i>Pharmacoeconomics</i> , 2019, 37, 239-253.	1.7	10
34	Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review. <i>Rheumatology and Therapy</i> , 2019, 6, 89-100.	1.1	8
35	Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review. <i>Drugs - Real World Outcomes</i> , 2019, 6, 1-9.	0.7	2
36	Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States. <i>Journal of Medical Economics</i> , 2018, 21, 577-586.	1.0	14

#	ARTICLE	IF	CITATIONS
37	Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer. <i>Clinical Therapeutics</i> , 2018, 40, 628-639.e3.	1.1	9
38	Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States. <i>Current Medical Research and Opinion</i> , 2018, 34, 585-592.	0.9	4
39	Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1267-1277.	0.9	15
40	Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis. <i>Current Medical Research and Opinion</i> , 2018, 34, 1645-1652.	0.9	10
41	A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1058-1066.	1.0	3
42	Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective. <i>Blood</i> , 2018, 132, 3535-3535.	0.6	4
43	Indirect treatment comparison of blinatumomab versus inotuzumab ozogamicin for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy. <i>Journal of Clinical Oncology</i> , 2018, 36, e19000-e19000.	0.8	1
44	Novel treatment (Tx) use and associated outcomes among African American patients (pts) with multiple myeloma (MM): A SEER-Medicare analysis. <i>Journal of Clinical Oncology</i> , 2018, 36, e20030-e20030.	0.8	1
45	Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. <i>European Child and Adolescent Psychiatry</i> , 2017, 26, 875-897.	2.8	26
46	Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 55-62.e3.	0.6	10
47	First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. <i>Current Medical Research and Opinion</i> , 2017, 33, 2137-2143.	0.9	2
48	Impact of Teduglutide and Parenteral Nutrition (PN) Volume Reduction on Quality of Life (QoL) in Patients with Short Bowel Syndrome and PN Dependency. <i>Transplantation</i> , 2017, 101, S66.	0.5	3
49	Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer. <i>Advances in Therapy</i> , 2017, 34, 2566-2584.	1.3	4
50	Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1167-1178.	0.9	21
51	Impact of FDA approval of lenalidomide maintenance therapy in the first-line treatment of multiple myeloma after autologous stem cell transplant on total healthcare costs. <i>Journal of Clinical Oncology</i> , 2017, 35, e19509-e19509.	0.8	2
52	Real-world palbociclib dosing patterns and potential wastage associated with dose modifications among post-menopausal women with HR-positive/HER2-negative metastatic breast cancer (mBC). <i>Journal of Clinical Oncology</i> , 2017, 35, 17-17.	0.8	0
53	Comparative efficacy with endocrine-based combination versus monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: A network meta-analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, e12535-e12535.	0.8	0
54	Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors. <i>American Health and Drug Benefits</i> , 2017, 10, 408-415.	0.5	12

#	ARTICLE	IF	CITATIONS
55	Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. <i>Journal of Blood Medicine</i> , 2016, Volume 7, 129-137.	0.7	11
56	Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada. <i>Journal of Medical Economics</i> , 2016, 19, 936-944.	1.0	12
57	Physician experiences and preferences in the treatment of HR +/ HER 2 ⁺ metastatic breast cancer in the United States: a physician survey. <i>Cancer Medicine</i> , 2016, 5, 209-220.	1.3	10
58	Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2 ⁺ mBC Patients With Multiple Metastatic Sites. <i>Clinical Therapeutics</i> , 2016, 38, 905-917.	1.1	2
59	Disparities in treatment patterns and outcomes between Caucasian and African American patients with multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8022-8022.	0.8	7
60	Clinical outcomes among HR+/HER2 ⁺ metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. <i>Experimental Hematology and Oncology</i> , 2015, 4, 31.	2.0	12
61	Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2 ⁺ Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. <i>International Journal of Breast Cancer</i> , 2015, 2015, 1-9.	0.6	15
62	Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2 ⁺ metastatic breast cancer: a retrospective chart review in community oncology practices in the US. <i>Current Medical Research and Opinion</i> , 2015, 31, 1095-1103.	0.9	9
63	Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder. <i>Value in Health</i> , 2015, 18, 824-831.	0.1	7
64	Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2015, 31, 1573-1582.	0.9	4
65	Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2 ⁺ Advanced Breast Cancer From a US Payer Perspective. <i>Clinical Breast Cancer</i> , 2015, 15, e263-e276.	1.1	21
66	Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2101-2111.	0.9	2
67	Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR+/HER2- metastatic breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 315-326.	0.6	2
68	Patterns of Prior Treatment and Bleeds Among Patients with Severe Hemophilia a: Impact on Frequency of Dosing with Bay 81-8973 in the Leopold I Trial. <i>Blood</i> , 2015, 126, 1103-1103.	0.6	3
69	Systematic literature review (SLR) of clinical and real-world observational studies of octreotide LAR for treatment of neuroendocrine tumors (NETs).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15190-e15190.	0.8	0
70	Comparative effectiveness of everolimus versus chemotherapies among post-menopausal women with HR+/HER2- metastatic breast cancer: A retrospective chart review of community oncology practices in the US.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11520-e11520.	0.8	0
71	Comparative effectiveness of everolimus versus endocrine monotherapies among post-menopausal women with HR+/HER2- metastatic breast cancer: A retrospective chart review of community oncology practices in the US.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11527-e11527.	0.8	0
72	Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1543.	1.0	149

#	ARTICLE	IF	CITATIONS
73	Associations Between Joint Damage and Quality of Life Among Patients with Severe Hemophilia a in the 3-Year Spinart Trial. <i>Blood</i> , 2014, 124, 200-200.	0.6	1
74	Comparison of Real-World Treatment Patterns and Clinical Outcomes in 18-59 Year-Old Patients with FLT3 Mutated Vs. FLT3 Wild Type Acute Myeloid Leukemia: A Medical Records Review. <i>Blood</i> , 2014, 124, 5992-5992.	0.6	0
75	Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. <i>Journal of Medical Economics</i> , 2013, 16, 278-288.	1.0	17
76	Abstract WP383: An Economic Model of Improved Acute Stroke Care in the Management of Acute Ischemic Stroke From A State Medicaid Perspective. <i>Stroke</i> , 2013, 44, .	1.0	0
77	Cost-Effectiveness of Denosumab Compared With Zoledronic Acid in Patients With Breast Cancer and Bone Metastases. <i>Clinical Breast Cancer</i> , 2012, 12, 247-258.	1.1	26
78	Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 621-643.	2.2	52